Evidence-informed educational review. Updated 10 November 2026. Follow current local product labeling and individualized clinical guidance.
Classification and mechanism
Omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole are substituted benzimidazole prodrugs. Dexlansoprazole is the R-enantiomer of lansoprazole. Drug activation occurs in the acidic canaliculus of the gastric parietal cell, where active sulfenamide intermediates bind the luminal H+/K+-ATPase irreversibly. This pump is located in the apical secretory membrane. Clinical effects persist beyond the short plasma half-life while new proton pumps are synthesized [1].
Timing treatment for reflux
For typical heartburn or regurgitation without alarm features, the American College of Gastroenterology recommends an initial eight-week trial of a once-daily PPI. Most conventional delayed-release products work best taken 30–60 minutes before breakfast. If twice-daily therapy is indicated, time the second dose before the evening meal. Check the formulation instructions because some products have different food requirements. [2]
When symptoms persist, first ask when the patient actually takes the medicine and which symptom remains. Dysphagia, gastrointestinal bleeding or unexplained weight loss warrants investigation. For severe erosive esophagitis (Los Angeles grade C or D), long-term maintenance or antireflux surgery may be appropriate. Patients with uncomplicated symptoms that resolve can often try discontinuation or on-demand therapy. [2]
Uses beyond reflux
A PPI supports ulcer healing and forms part of several Helicobacter pylori eradication regimens. Successful treatment requires effective antibiotics and subsequent testing to confirm eradication. In high-risk bleeding ulcers treated endoscopically, intensive short-term acid suppression helps reduce rebleeding. These indications have different doses, treatment durations and follow-up requirements. [3, 4]
Safety and review of ongoing treatment
Review the other medicines before selecting a PPI. Omeprazole inhibits CYP2C19 and can reduce formation of clopidogrel’s active metabolite. Its US label advises avoiding this combination. Acute tubulointerstitial nephritis can occur during treatment. Prolonged exposure can also contribute to hypomagnesemia in susceptible patients. Choose monitoring according to risk factors and concomitant drugs. Observational associations with several chronic diseases do not by themselves establish that PPIs caused them. [5, 2]
Record the indication when renewing treatment. If it has resolved, discuss dose reduction or discontinuation and explain that transient rebound symptoms can follow withdrawal. Before deprescribing, assess upper gastrointestinal bleeding risk. A history of severe erosive disease, a peptic stricture or Barrett’s esophagus generally favours continued therapy. For patients with an ongoing indication, regularly review the lowest effective maintenance dose. [6, 2]
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline: guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117:27–56. [cited 2026 Nov 10]. View source.
- Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119:1730–1753. [cited 2026 Nov 10]. View source.
- Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116:899–917. [cited 2026 Nov 10]. View source.
- National Library of Medicine. Omeprazole delayed-release capsules. DailyMed prescribing information. [cited 2026 Nov 10]. View source.
- American Gastroenterological Association. De-prescribing proton pump inhibitors (PPIs). 2022. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.